Cargando…
Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias
STUDY OBJECTIVE: To estimate the incidence of 10 common cancers among patients treated with antimuscarinic medications for overactive bladder (AMOABs). DESIGN: Retrospective cohort study. DATA SOURCE: United Kingdom's Clinical Practice Research Datalink. PATIENTS: A total of 119,912 adults with...
Autores principales: | Kaye, James A., Margulis, Andrea V., Fortuny, Joan, McQuay, Lisa J., Plana, Estel, Bartsch, Jennifer L., Bui, Christine L., Perez‐Gutthann, Susana, Arana, Alejandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518180/ https://www.ncbi.nlm.nih.gov/pubmed/28370075 http://dx.doi.org/10.1002/phar.1932 |
Ejemplares similares
-
Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom
por: Margulis, Andrea V., et al.
Publicado: (2018) -
Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study
por: Arana, Alejandro, et al.
Publicado: (2018) -
Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom
por: Margulis, Andrea V., et al.
Publicado: (2018) -
Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom
por: Arana, Alejandro, et al.
Publicado: (2020) -
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
por: Hoffman, Veena, et al.
Publicado: (2021)